Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR)

Pfizer, NCT05011513, EPIC-SR, NCT05011513
Jun 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 67% Improvement Relative Risk Hospitalization 52% Progression 4% Time to sustained allevia.. 8% Change in viral load 4% Paxlovid  EPIC-SR  EARLY TREATMENT  DB RCT Is early treatment with paxlovid beneficial for COVID-19? Double-blind RCT 1,288 patients in multiple countries (Aug 2021 - Jul 2022) Improved viral clearance with paxlovid (p=0.039) c19early.org Pfizer, NCT05011513, June 2022 Favorspaxlovid Favorscontrol 0 0.5 1 1.5 2+
Results for the terminated and unpublished (until April 2024) EPIC-SR trial.
risk of death, 67.0% lower, RR 0.33, p = 0.49, treatment 0 of 654 (0.0%), control 1 of 634 (0.2%), NNT 634, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 28.
risk of hospitalization, 51.5% lower, RR 0.48, p = 0.20, treatment 5 of 654 (0.8%), control 10 of 634 (1.6%), NNT 123, day 28.
risk of progression, 3.8% lower, RR 0.96, p = 0.21, treatment 494 of 654 (75.5%), control 498 of 634 (78.5%), NNT 33, day 28.
relative time to sustained alleviation, 7.7% lower, relative time 0.92, p = 0.16, treatment mean 12.0 (±13.0) n=654, control mean 13.0 (±12.8) n=634.
relative change in viral load, 3.9% better, RR 0.96, p = 0.04, treatment mean 5.46 (±1.84) n=654, control mean 5.25 (±1.89) n=634, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pfizer et al., 14 Jun 2022, Double Blind Randomized Controlled Trial, multiple countries, preprint, 1 author, study period 25 August, 2021 - 25 July, 2022, trial NCT05011513 (history) (EPIC-SR).
This PaperPaxlovidAll
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit